IXICO plc IXICO to Present at SCA & ARCA Global Conference
19 October 2020 - 5:00PM
RNS Non-Regulatory
TIDMIXI
IXICO plc
19 October 2020
This is an RNS Reach announcement and the information contained
is not considered to be material or to have a significant impact on
management's expectations of the Group's performance. RNS Reach is
an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute
non-regulatory news releases into the public domain. Information
required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an
RNS regulatory announcement and not on RNS Reach.
IXICO plc
("IXICO" or the "Company")
IXICO to Present at SCA & ARCA Global Conference
IXICO plc (AIM: IXI), the AI data analytics company delivering
insights in neuroscience , announces that Dr Robin Wolz, Senior
Vice President of Science & Innovation at IXICO, will present
on the industry panel at the virtual SCA & ARCA Global
Conference, taking place on 19-21 October 2020.
The SCA & ARCA Global Conference brings together two
initiatives that focus on ataxia, which is the loss of coordination
of voluntary muscle movements. This platform allows for academic
and industry leaders, physicians and companies working in the space
to collaborate on developing future treatments for patients.
Autosomal-recessive cerebellar ataxias (ARCA) are a
heterogeneous group of rare degenerative and metabolic genetic
diseases recessively inherited and spinocerebellar ataxias (SCAs)
are a group of autosomal dominantly inherited progressive ataxia
disorders. The clinical manifestations of hereditary ataxias are
poor coordination of movement and unsteady gait.
Dr Robin Wolz will be presenting on the industry panel on 20
October at 16.20 (BST). The talk is titled: "Challenges and
opportunities in the deployment of volumetric MRI in SCA clinical
trials ." Additionally, IXICO are supporting the conference as an
official partner of SCA & ARCA Global 2020.
Dr Robin Wolz, Senior Vice President, Science & Innovation
at IXICO commented: "Ataxia conditions continue to be a focus for
IXICO in its efforts to provide pioneering technologies to support
the advancement of effective treatments for rare neurological
diseases. Our research in imaging analytics will provide an insight
into the best methods for monitoring both the progression of the
disease as well as the potential effect of interventional
treatments."
Additional info can be found on the conference website:
http://ataxia-global-initiatives.net/sca-global/conferences/sca-global-2020/
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales)
Walbrook PR Ltd Tel: +44 (0) 20 7933 8780 or IXICO@walbrookpr.com
Paul McManus / Lianne Cawthorne / Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
mission is to transform the progression of our biopharmaceutical
clients' neurological therapeutic pipelines through the application
of novel imaging and digital biomarkers.
IXICO's data analytics services are used by the global
biopharmaceutical industry to interpret data from brain scans and
digital biosensors to enable better trial design, site
qualification, patient selection and clinical outcomes. We provide
technology-enabled services across all phases of clinical
evaluation. Our integrated digital platform provides a scalable and
secure infrastructure for the capture and analysis of regulatory
compliant clinical data to enable clients to make rapid, better
informed decisions. IXICO is also collaborating with partners to
develop new analytical techniques and companion digital health
products targeted at improving patient outcomes.
More information is available on www.IXICO.com and follow us on
Twitter @IxicOplc
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAZZMMGRVDGGZM
(END) Dow Jones Newswires
October 19, 2020 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024